Natco, Cipla gain after Supreme Court dismisses Novartis petition

Reuters Market Eye - Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.

In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.

Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as other emerging countries are also expected to follow he apex court's decision.

Cipla and Natco are already selling generic versions of Glivec in India. Natco ended up 5.4 percent, while Cipla rose 1.3 percent.

(Reporting by Abhishek Vishnoi)

Updated Date: Apr 02, 2013 04:00 AM

Also Watch

Watch: Firstpost test rides the new Thunderbird 500X in Goa and walks you through the Royal Enfield Garage Cafe
  • Tuesday, April 17, 2018 Varun Dhawan on Shoojit Sircar's October, 5-star reviews and working with Anushka Sharma in Sui Dhaaga
  • Saturday, April 14, 2018 Ambedkar Jayanti: Re-visiting Babasaheb's ideals exposes fake Dalit politics of Rahul Gandhi and Congress
  • Monday, April 9, 2018 48 hours with Huawei P20 Pro: Triple camera offering is set to redefine smartphone imaging
  • Monday, April 16, 2018 Rajyavardhan Singh Rathore interview: Sports can't be anyone's fiefdom, we need an ecosystem to nurture raw talent

Also See